Bismuth Subcitrate [Discontinued in SA Market]

Please note that the products associated with this active ingredient monograph have all been discontinued in the South African market.

The information in this monograph has not been updated and remains on the EMGuidance platform for reference purposes only.

• Duodenal ulcers
• Gastric ulcers
• Gastritis

Please note that the products associated with this active ingredient monograph have all been discontinued in the South African market.

The information in this monograph has not been updated and remains on the EMGuidance platform for reference purposes only.

Contraindications

• Hypersensitivity to the active ingredient or any of its excipients
• Pregnancy
• Lactation
• Renal impairment
• Patients on a low potassium diet
• Patients who have colostomies or ileostomies

Cautions

• Hepatic impairment
• Elderly
• Prolonged use
• Controlled potassium diet

Please note that the products associated with this active ingredient monograph have all been discontinued in the South African market.

The information in this monograph has not been updated and remains on the EMGuidance platform for reference purposes only.

Duodenal ulcers
Gastric ulcers

• Oral (tab): 240mg, 2-3 times a day on an empty stomach (half an hour before meals); Treatment duration: 4-8 weeks

Maintenance therapy is not recommended, although treatment may be resumed after a bismuth subcitrate -free interval of one month

Gastritis (additional agents required)
- Adjunct treatment of gastritis due to Helicobacter pylori

• Oral (tab): 120mg, 4 times a day on an empty stomach (half an hour before meals); Treatment duration: 7 days

No liquid is to be taken 30 minutes before or after each dose

Swallow whole - Do not chew

Please note that the products associated with this active ingredient monograph have all been discontinued in the South African market.

The information in this monograph has not been updated and remains on the EMGuidance platform for reference purposes only.

No information available

Please note that the products associated with this active ingredient monograph have all been discontinued in the South African market.

The information in this monograph has not been updated and remains on the EMGuidance platform for reference purposes only.

Pregnancy

• Contraindicated
• Bismuth trioxide is contraindicated in pregnancy

Breastfeeding

• Contraindicated
• No information is available on excretion in breast milk. Safety in breastfeeding has not been established

Renal Impairment

• Contraindicated

Hepatic Impairment

• Caution; no information available

Elderly

• Caution; no information available

Porphyria Information

• Probably not porphyrinogenic (PNP)

Drugs in Sport

• Permitted - No warnings

Please note that the products associated with this active ingredient monograph have all been discontinued in the South African market.

The information in this monograph has not been updated and remains on the EMGuidance platform for reference purposes only.

Gastrointestinal Disorders

Very common

• Blackening of stool and tongue

Uncommon

• Nausea and vomiting
• Constipation
• Diarrhoea and pain

Skin and Subcutaneous Tissue Disorders

Uncommon

• Rash
• Pruritus

Immune, Blood and Lymphatic System Disorders

Frequency unknown

• Anaphylactic reaction

Please note that the products associated with this active ingredient monograph have all been discontinued in the South African market.

The information in this monograph has not been updated and remains on the EMGuidance platform for reference purposes only.

• Tetracyclines
• Antacids

Other interactions

• Alcohol
• Food or drink
• Milk
• Fruit or fruit juices

Please note that the products associated with this active ingredient monograph have all been discontinued in the South African market.

The information in this monograph has not been updated and remains on the EMGuidance platform for reference purposes only.

None routine

Please note that the products associated with this active ingredient monograph have all been discontinued in the South African market.

The information in this monograph has not been updated and remains on the EMGuidance platform for reference purposes only.

Tripotassium dicitrato bismuthate is a colloidal bismuth hydrosol which has the ability to combine with the necrotic protein material oozing from the ulcer bed and form a bismuth-protein chelate over the ulcer base (surface).

Tablet 120mg

• Denol (Astellas) originator - Discontinued